Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
AVNR > SEC Filings for AVNR > Form 8-K on 19-Mar-2014All Recent SEC Filings

Show all filings for AVANIR PHARMACEUTICALS, INC.

Form 8-K for AVANIR PHARMACEUTICALS, INC.


19-Mar-2014

Change in Directors or Principal Officers


Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 19, 2014, Avanir Pharmaceuticals, Inc. (the "Company") announced that Mark Corrigan, M.D. was appointed a Class III director effective March 18, 2014, to serve until the expiration of his term at the 2016 annual meeting of stockholders. Concurrent with Dr. Corrigan's appointment, the size of the Board was fixed at seven directors, consisting of two Class I directors, two Class II directors and three Class III directors. In connection with his appointment to the Board of Directors, Dr. Corrigan was also appointed as a member of the Corporate Governance Committee and chairperson of the Science Committee.

Dr. Corrigan currently serves as President and Chief Executive Officer of Zalicus Inc. (formerly known as CombinatoRx, Incorporated), or Zalicus, a public biopharmaceutical company, a position he has held since January 2010. He has also served as a director of Zalicus and its progenitor companies since December 2006. Prior to Zalicus, Dr. Corrigan joined Sepracor, Inc. (now known as Sunovion Pharmaceuticals, Inc.), a pharmaceutical company, in 2003 and served as their Executive Vice President, Research and Development until December 2009. Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, a pharmaceutical company acquired by Pfizer, Inc. in 2003, most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Prior to joining the pharmaceutical industry, Dr. Corrigan spent five years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology. Dr. Corrigan has also been a member of the Board of Directors and audit committee of Cubist Pharmaceuticals, Inc. since June 2008. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and subsequently received specialty training in Psychiatry at Cornell and Maine Medical Center.

* * *

-2-


  Add AVNR to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for AVNR - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.